Medtronic (NYSE:MDT) Releases FY 2027 Earnings Guidance

Medtronic (NYSE:MDT) issued an update on its FY 2027 earnings guidance on Tuesday morning. The company provided earnings per share guidance of 5.940-6.000 for the period, compared to the consensus estimate of 5.950. The company issued revenue guidance of -. Medtronic also updated its Q2 2027 guidance to 1.320-1.340 EPS.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on MDT shares. BTIG Research boosted their target price on Medtronic from $91.00 to $100.00 and gave the stock a “buy” rating in a research report on Tuesday. Leerink Partners dropped their target price on shares of Medtronic from $117.00 to $104.00 and set an “outperform” rating on the stock in a research report on Thursday, June 4th. UBS Group upgraded shares of Medtronic from a “neutral” rating to a “buy” rating and upped their price target for the company from $85.00 to $100.00 in a research report on Tuesday, July 28th. Truist Financial reiterated a “hold” rating and set a $99.00 price objective (up from $86.00) on shares of Medtronic in a research report on Wednesday. Finally, Wall Street Zen raised Medtronic from a “hold” rating to a “buy” rating in a research report on Saturday, July 18th. Nineteen analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $102.96.

Medtronic Stock Performance

Shares of NYSE MDT opened at $92.10 on Thursday. The business’s 50-day simple moving average is $86.27 and its 200-day simple moving average is $85.35. Medtronic has a 52 week low of $73.31 and a 52 week high of $106.33. The company has a debt-to-equity ratio of 0.52, a quick ratio of 1.62 and a current ratio of 2.13. The firm has a market cap of $117.89 billion, a price-to-earnings ratio of 22.69, a P/E/G ratio of 2.15 and a beta of 0.56.

Medtronic (NYSE:MDT) last posted its quarterly earnings data on Tuesday, September 1st. The medical technology company reported $1.45 EPS for the quarter, topping analysts’ consensus estimates of $1.39 by $0.06. The business had revenue of $9.76 billion for the quarter, compared to analyst estimates of $9.55 billion. Medtronic had a return on equity of 14.89% and a net margin of 13.93%.The firm’s revenue for the quarter was up 13.7% on a year-over-year basis. During the same period in the previous year, the company posted $1.26 earnings per share. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. As a group, equities research analysts expect that Medtronic will post 5.96 earnings per share for the current fiscal year.

Medtronic Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 16th. Shareholders of record on Friday, September 25th will be issued a $0.72 dividend. This represents a $2.88 annualized dividend and a yield of 3.1%. The ex-dividend date of this dividend is Friday, September 25th. Medtronic’s payout ratio is 70.94%.

Insider Activity

In other news, EVP Harry Skip Kiil sold 4,189 shares of the stock in a transaction on Monday, June 8th. The shares were sold at an average price of $80.44, for a total value of $336,963.16. Following the completion of the transaction, the executive vice president owned 37,227 shares in the company, valued at approximately $2,994,539.88. This represents a 10.11% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 0.27% of the company’s stock.

Medtronic News Roundup

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Beat-and-raise results: Medtronic reported fiscal Q1 FY2027 adjusted EPS of $1.45, ahead of the $1.39 consensus, while revenue increased 13.7% year over year to $9.76 billion, exceeding estimates. Growth was broad-based, led by cardiovascular sales, with additional contributions from neuroscience, medical surgery and diabetes. Medtronic Q1 Earnings and Revenues Top Estimates
• Positive Sentiment: Higher fiscal-year outlook: Management raised fiscal 2027 organic revenue-growth guidance to 7.25%-7.75% and adjusted EPS guidance to $5.94-$6.00. Analysts viewed the update as evidence that growth is accelerating across the portfolio, although the outlook benefited from an extra fiscal week in the quarter. Medtronic Begins Fiscal 2027 With a Beat-and-Raise
• Positive Sentiment: Robotics and heart-tech expansion: Medtronic committed approximately $700 million to a strategic partnership with Cornerstone Robotics, gaining rights to distribute its Sentire surgical system in select markets outside the United States. It also plans to invest up to $80 million in Pi-Cardia to support complex transcatheter aortic-valve replacement procedures. These deals broaden Medtronic’s growth platforms alongside its Hugo robotic system. Medtronic Announces Strategic Partnership with Cornerstone Robotics
• Positive Sentiment: Supportive analyst views and trading activity: RBC reaffirmed an Outperform rating with a $118 target, while BTIG raised its target to $100 and kept a Buy rating. Unusually heavy call-option activity also indicates increased speculative interest following the earnings report. Medtronic Analysts Raise Their Forecasts
• Neutral Sentiment: Stifel raised its price target to $95 but retained a Hold rating, and Baird lifted its target to $100 while maintaining Neutral, signaling that valuation and execution remain considerations despite the improved outlook. Medtronic Shares Gap Up on Better-Than-Expected Earnings

Hedge Funds Weigh In On Medtronic

Several large investors have recently made changes to their positions in MDT. Acumen Wealth Advisors LLC acquired a new stake in Medtronic in the fourth quarter worth about $29,000. Imprint Wealth LLC acquired a new position in shares of Medtronic in the 3rd quarter valued at $31,000. JPL Wealth Management LLC bought a new position in Medtronic during the third quarter worth about $40,000. Chapman Financial Group LLC acquired a new position in shares of Medtronic during the 2nd quarter worth about $37,000. Finally, Caitong International Asset Management Co. Ltd increased its stake in shares of Medtronic by 96.5% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 454 shares of the medical technology company’s stock valued at $44,000 after acquiring an additional 223 shares during the last quarter. Institutional investors and hedge funds own 82.06% of the company’s stock.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).